Cholesterol-focused Esperion loses appetite for oral PCSK9 collab with Serometrix

Cholesterol-focused Esperion loses appetite for oral PCSK9 collab with Serometrix

Submitted by admin on August 1, 2023 - 11:57am
Source: 
Fierce Biotech
News Tags: 
Esperion Therapeutics
R&D
Serometrixjm
PCSK9 inhibitors
cholesterol
Headline: 
Cholesterol-focused Esperion loses appetite for oral PCSK9 collab with Serometrix
snippet: 

Esperion Therapeutics is ending an R&D collaboration with Serometrix centered on the former's oral PCSK9 candidate, two and a half years after paying $12.5 million to partner up. 

Do Not Allow Advertisers to Use My Personal information